Uniphar stock
UPR.IRDUBUniphar plc, HealthcareISIN IE00BJ5FQX74
57Score 57 out of 100, Neutral
Price and trend
58 / 100
Price history
+11% in one yearThe chart shows daily closes over 7 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 3.5% above it.
Since October 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Overheated: the price has risen very quickly lately (RSI 82).
The price is 11% below its 52-week high. Largest decline in 7 years: 61% (December 2021 to January 2025).
Chart figures for advanced users
- SMA 50$4.49
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$4.67
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)82
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$3.79
- The lowest closing price of the last twelve months.
- Resistance$5.45
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Uniphar plc belongs to the Medical (Distribution) industry (Ireland) and, with a market value of $1.25B, is number 12 of 17 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $3.41B (up 11% year on year) and earnings of $56.61M (down 20.4%).
- For fiscal 2026, analysts expect on average revenue of $3.59B (up 5.3%) and adjusted earnings per share of $0.30 (down 0.8%).
Show more
- MEQIRI Score 57 out of 100 (Neutral): rank 322 of 716 in Healthcare, median 53.
- The P/E is 21.1 (Medical (Distribution) median 26.9, own median of recent years 17.6).
- Our model puts fair value at $6.23, with the price 22% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Earnings per share growingUp 12.7% a year since 2020.Growth 55
Weaknesses
- High debtDebt 1.22 times equity (latest quarter), Medical (Distribution) median 0.74.Stability 55
The score is held back by profitability.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
The fundamentals are in the middle range.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among smaller stocks.
From 2016 to 2025, 20 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
Valuation
Valuation signal
Modestly undervaluedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $4.79 and expensive above $8.90 (uncertainty medium, based on the price swings of the past year).
The two parts of the fair value come to $6.31 (cash-flow model) and $6.15 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is below both.
Calculated with a cost of equity of 9.7%. At 10.7% the fair value would be $5.80, at 8.7% it would be $6.80.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (26.9).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Jun 2026, revenue rose 10.1% on the twelve months before. Revenue has grown solidly since 2013, at about 11% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 15%, operating 3%, net 2%.
Debt & balance sheet
latest quarterDebt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 2 Mar 2027in 109 days
- Last reported
- 8 Sep 2026EPS reported $0.12
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $0.300.0%
- Revenue
- $3.59B0.0%
- Earnings per share
- $0.310.0%
- Revenue
- $3.77B0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
What happened at Uniphar
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
716 rated companies in Healthcare
- This company
- 57
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Distribution)
The next larger and next smaller companies by market value
- AmplifonAMP.MI $3.68B49
- Asker Healthcare GroupASKER.ST $2.87B61
- Sopharma ADSPH.WA $1.9B57
- Redcare PharmacyRDC.DE $1.6B47
- Akso Health GroupAHG $1.15B36
- DocMorrisDOCM.SW $1.14B39
- ArjoARJO-B.ST $927.89M58
- Neuca S.a.NEU.WA $788.51M59
ETFs that hold Uniphar
Held by 14 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares MSCI EMU Small Cap UCITS ETFSXRJ | 0.19% | 0.58% | €834.67M |
| WisdomTree Europe SmallCap Dividend UCITS ETFWTES | 0.09% | 0.38% | €86.74M |
| State Street SPDR MSCI Europe Small Cap Value Weighted UCITS ETF EUR AccZPRX | 0.08% | 0.30% | €810.11M |
Show 5 more
| Xtrackers MSCI Europe Small Cap UCITS ETF 1CXXSC | 0.07% | 0.30% | €3.43B |
| Amundi MSCI EMU Small Cap ESG Broad Transition UCITS ETF DISTLGWU | 0.05% | 0.40% | €575.19M |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.05% | 0.35% | €434.1M |
| UBS MSCI EMU Select Factor Mix UCITS ETF EUR accUIQN | 0.03% | 0.34% | €16.87M |
| Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF DistX026 | 0.02% | 0.23% | €319.31M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = €0.9024)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 31 Jul 2020)
- Valuation signal Fairly valued since 7 Nov 2026, previously Undervalued
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.